Brittany Renae Brown, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1615 Curlew Dr, Ammon, ID 83406 Phone: 208-516-1204 Fax: 208-577-6477 |
Peak Performance Therapy Services P C Physical Therapist Medicare: Medicare Enrolled Practice Location: 3456 E 17th St, Suite 130, Ammon, ID 83406 Phone: 208-523-0030 Fax: 208-523-3828 |
Phares Briggs Horman, P.T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 3456 E 17th St, Suite 130, Ammon, ID 83406 Phone: 208-523-0030 |
Vista Physical Therapy, Pllc Physical Therapist Medicare: Medicare Enrolled Practice Location: 1615 Midway Dr, Ammon, ID 83406 Phone: 208-529-1715 |
Michael Cuthbertson, D.P.T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 3456 E 17th St Ste 130, Ammon, ID 83406 Phone: 208-523-0030 Fax: 208-523-3828 |
Achieve Therapy And Learning Services, Llc Physical Therapist Medicare: Medicare Enrolled Practice Location: 1979 Eagle Pointe Ct, Ammon, ID 83406 Phone: 208-589-8381 |
Lindsay Ann Rankin, PT, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 2785 Eagle Dr Apt G106, Ammon, ID 83406 Phone: 801-602-2651 |
Mark S Taylor, PT Physical Therapist - Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 3800 Taylorview Ln, Ammon, ID 83406 Phone: 208-535-0057 |
Mason Dale Orton, DPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 1615 Curlew Dr, Ammon, ID 83406 Phone: 208-516-1204 Fax: 208-577-6477 |
Heidi Duran, DPT Physical Therapist - Orthopedic Medicare: Accepting Medicare Assignments Practice Location: 3456 E 17th St, #130, Ammon, ID 83406 Phone: 208-523-0030 |
Kevin Nelson Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1480 Midway Ave, Ammon, ID 83406 Phone: 208-523-1980 Fax: 208-523-4024 |
Fit Technologies Llc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 2475 S Ammon Rd, Ammon, ID 83406 Phone: 208-523-7993 |
Colby C Ebanks, PT, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1615 Curlew Dr, Ammon, ID 83406 Phone: 208-516-1204 Fax: 208-577-6477 |
Christopher Dahle, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1615 Curlew Dr, Ammon, ID 83406 Phone: 208-516-1204 Fax: 208-577-6744 |
Ryan Jay Estus, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1615 Curlew Dr, Ammon, ID 83406 Phone: 208-516-1204 Fax: 208-577-6477 |
Keegan Parmer, DPT Physical Therapist - Orthopedic Medicare: Accepting Medicare Assignments Practice Location: 1615 Midway Dr, Ammon, ID 83406 Phone: 208-529-1715 |
Levi Peterson Williams, DPT, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1615 Curlew Dr, Ammon, ID 83406 Phone: 208-516-1204 Fax: 208-577-6477 |
News Archive
Elusys Therapeutics, Inc. today announced the U.S. Food and Drug Administration has accepted for filing and review its Biologics License Application for AnthimĀ® (obiltoxaximab) for the treatment and prevention of inhalational anthrax, a top bioterror threat which was submitted on March 20, 2015. Anthim is a candidate for future acquisition into the Strategic National Stockpile, the U.S. government's repository of critical medical supplies for biowarfare preparedness.
Gestational age has long been the factor most commonly used to predict whether an extremely low-birth-weight infant survives and thrives, but four additional factors that can help predict a preemie's outcome have been identified by the National Institutes of Health Neonatal Research Network, of which Yale is a member.
A group of leading chemotherapy experts assembled as the Clinical Oncologists for Individualized Therapy (COFIT) refute the findings of the American Society of Clinical Oncology (ASCO) technology assessment panel regarding the use of chemotherapy sensitivity and resistance assays (CSRAs).
A study led by researchers at the Keck School of Medicine of the University of Southern California (USC) has found that one of seven genetic risk factors previously identified as increasing the probability of developing prostate cancer also increases the probability of developing colorectal cancer.
MedImmune today announced that clinical results of its pivotal multinational, randomized, double-masked trial for motavizumab have been published in the current issue of the peer-reviewed publication, Pediatrics: Official Journal of the American Academy of Pediatrics.
› Verified 3 days ago